Where does GRI stock trade?

GRI Bio Inc. (GRI) is listed on NASDAQ.

What sector and industry is GRI in?

GRI Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did GRI Bio Inc. go public?

GRI Bio Inc. (GRI) completed its IPO in 2021.

What are analysts saying about GRI?

GRI Bio Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $1000.00 price target on 2024-12-09. Recent price targets cluster around $1000.00.

What companies are similar to GRI?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GRI side-by-side with any of them on Quantisnow.

How can I track GRI on Quantisnow?

Quantisnow aggregates GRI Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GRI to receive live email and push alerts on every new disclosure.

GRI

NASDAQ

GRI Bio Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2021

News25/Ratings1

News · 26 weeks30-60%

2025-12-282026-06-21

Mix890d

Other5(63%)
SEC Filings3(38%)

Latest news

25 items

4dSEC
GRI Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - GRI Bio, Inc. (0001824293) (Filer)
4dPR
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a progressive, irreversible and ultimately fatal lung disease affecting tens of thousands of patients in the United States. The designation represents a significant regulatory
35dPR
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026. Management will discuss the Company's differentiated immune-modulating pipeline, inclu
39dSEC
GRI Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
8-K - GRI Bio, Inc. (0001824293) (Filer)
39dPR
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in combination Advancing GRI-0803 toward IND-enabling activities to expand the pipeline across autoimmune indications with high unmet need LA JOLLA, CA, May 14, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced reported financial results for the quarter ended March 31,
40dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by GRI Bio Inc.
SCHEDULE 13G/A - GRI Bio, Inc. (0001824293) (Subject)
40dSEC
SEC Form 10-Q filed by GRI Bio Inc.
10-Q - GRI Bio, Inc. (0001824293) (Filer)
75dPR
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA, April 08, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has received a Notice of Allowance from the United Arab Emirates Patent Office (UAE) for UAE Patent No. P6000687/2017, titled "Prevention and Treatment of Inflammatory Conditions." The allowed claims cover novel t
129dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by GRI Bio Inc.
SCHEDULE 13G/A - GRI Bio, Inc. (0001824293) (Subject)
137dPR
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
– Live video webcast on Wednesday, February 11th at 1:00 PM EST LA JOLLA, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. Details of the presentation are as follows:Date and Time: Wednesday, February 11, 2026 at 1:00 PM ESTPresenter: Marc Hertz, PhD, President, Chief Executive Officer and DirectorRegistration Link: Here About Webull Financial
138dSEC
GRI Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - GRI Bio, Inc. (0001824293) (Filer)
138dPR
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into Q1 2027 Strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis reinforce clinical proof-of-concept and therapeutic differentiation GRI-0803 focused on autoimmune indications with high unmet need advancing through IND-enabling activities LA JOLLA, CA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and
141dSEC
SEC Form EFFECT filed by GRI Bio Inc.
EFFECT - GRI Bio, Inc. (0001824293) (Filer)
143dSEC
SEC Form 10-K filed by GRI Bio Inc.
10-K - GRI Bio, Inc. (0001824293) (Filer)
144dSEC
GRI Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - GRI Bio, Inc. (0001824293) (Filer)
144dSEC
SEC Form 424B5 filed by GRI Bio Inc.
424B5 - GRI Bio, Inc. (0001824293) (Filer)
144dSEC
SEC Form S-3 filed by GRI Bio Inc.
S-3 - GRI Bio, Inc. (0001824293) (Filer)
144dSEC
SEC Form S-8 filed by GRI Bio Inc.
S-8 - GRI Bio, Inc. (0001824293) (Filer)
145dSEC
GRI Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - GRI Bio, Inc. (0001824293) (Filer)
145dPR
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced additional positive data from its recently completed Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF"), further strengthening potential clinical proof-of-concept and reinforcing the therapeutic differentiation of GRI-0621. Newly reported RNA-sequencing differential gene expression data
147dPR
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,528,775, providing robust new intellectual property protection for novel compound compositions central to the Company's platform of immunomodulators. The newly issued patent includes composition-of-matter c
152dSEC
GRI Bio Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
8-K - GRI Bio, Inc. (0001824293) (Filer)
152dPR
GRI Bio Announces Reverse Stock Split
GRI's common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-28 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on January 15, 2026. The Reverse Split will legally take effect at 4:01 p.m. Easte
157dSEC
GRI Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - GRI Bio, Inc. (0001824293) (Filer)
158dSEC
GRI Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events
8-K - GRI Bio, Inc. (0001824293) (Filer)

GRI FAQ

6 questions

Where does GRI stock trade?
GRI Bio Inc. (GRI) is listed on NASDAQ.
What sector and industry is GRI in?
GRI Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did GRI Bio Inc. go public?
GRI Bio Inc. (GRI) completed its IPO in 2021.
What are analysts saying about GRI?
GRI Bio Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $1000.00 price target on 2024-12-09. Recent price targets cluster around $1000.00.
What companies are similar to GRI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GRI side-by-side with any of them on Quantisnow.
How can I track GRI on Quantisnow?
Quantisnow aggregates GRI Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GRI to receive live email and push alerts on every new disclosure.